Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM7 | Q14831 | 9/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19200358 | 1.00 | GRM7 (1.00) | GRM7HRH3NPC1LMNARAB9A | |
| SCHEMBL19200240 | 1.00 | GRM7 (1.00) | GRM7HRH3NPC1LMNARAB9A | |
| SCHEMBL19200544 | 0.88 | GRM7 (1.00) | GRM7HRH3NPC1LMNARAB9A | |
| SCHEMBL19200942 | 0.88 | GRM7 (1.00) | GRM7HRH3NPC1LMNARAB9A | |
| SCHEMBL19200151 | 0.82 | GRM7 (0.70) | GRM7HRH3LMNAMAPTMTNR1A | |
| SCHEMBL19200911 | 0.81 | GRM7 (0.68) | GRM7HRH3NPC1LMNARAB9A | |
| SCHEMBL2076259 | 0.80 | GRM7 (0.66) | GRM7LMNAMAPTKMT2AMEN1 | |
| SCHEMBL20678694 | 0.80 | GRM7 (0.69) | GRM7HRH3 | |
| SCHEMBL20678657 | 0.80 | GRM7 (0.69) | GRM7HRH3 | |
| SCHEMBL19182929 | 0.80 | GRM7 (0.69) | GRM7HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017131221-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-03 | — | — | WO | disclosed |